Neuphoria Stock Crashes After Social Anxiety Trial Failure — What’s Next?
Neuphoria shares plunged about 67% in after-hours trading Oct. 20 after its lead drug BNC210 failed a Phase 3 trial for social anxiety disorder. The company halted its social anxiety program, began a strategic review, and said it would cut spending. NEUP stock dropped from $15.40 to near $4.05 before rebounding to $6.70 by Oct. 24. Neuphoria reported $14.2 million in cash as of June 30 and maintains a partnership with Merck.
